VEA
PMVP icon

Virtus ETF Advisers’s PMV Pharmaceuticals PMVP Stock Holding History

Virtus ETF Advisers’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,534
Closed -$102K – 457
2023
Q3 		$102K Sell
16,534
-1,650
-9% -$11.3K 0.06% 333
2023
Q2 		$114K Buy
18,184
+7,762
+74% +$40.7K 0.07% 335
2023
Q1 		$49.7K Sell
10,422
-4,003
-28% -$28.2K 0.03% 430
2022
Q4 		$125K Buy
14,425
+3,364
+30% +$35.9K 0.07% 404
2022
Q3 		$132K Buy
11,061
+75
+0.7% +$1.08K 0.05% 376
2022
Q2 		$157K Buy
10,986
+4,240
+63% +$61.7K 0.06% 316
2022
Q1 		$140K Sell
6,746
-405
-6% -$7.14K 0.06% 237
2021
Q4 		$165K Buy
7,151
+922
+15% +$22.3K 0.06% 310
2021
Q3 		$186K Sell
6,229
-327
-5% -$10.4K 0.08% 285
2021
Q2 		$224K Buy
+6,556
New +$219K 0.09% 263

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Virtus ETF Advisers's PMVP Position: Q4 2023 in Review

Virtus ETF Advisers sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 16,534 shares — an estimated $102K sold.

Virtus ETF Advisers first reported a position in PMVP in Q2 2021 and held it in 10 quarters. The position peaked at $224K in Q2 2021. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

  • Virtus ETF Advisers reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 16,534 PMV Pharmaceuticals shares in Q4 2023, an estimated $102K.
  • Virtus ETF Advisers first reported a position in PMV Pharmaceuticals in Q2 2021 and held it in 10 quarters.
  • Virtus ETF Advisers's PMV Pharmaceuticals position peaked at $224K in Q2 2021.
  • 98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.